leisure time -WSS

leisure time

author：focus 2025-10-01 20:16:16 - browse：5668

SAN DIEGO — After starting off the year with lower revenue projections than market analysts had hoped for, San Diego-based genomics giant Illumina lowered expectations again on Wednesday, forecasting annual growth of 1% compared to the previous year.

The market’s response was swift. Minutes after the company issued its press release, shares in Illumina dipped from $184.49 to below $172 during after-hours trading.

In its release, Illumina noted that it expects revenue from the company’s core business to be essentially the same this year compared to last, and that it expects revenue from Grail, the cancer diagnostics company that Illumina acquired for $8 billion in the fall of 2021, to remain in the range of $90 and $100 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： New guidelines on severe brain injury complicate already difficult decisions

WSS

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

The battle over the Brookhaven Landfill on Long Island

Cigna, Humana reportedly in talks to merge

Fetal surgery at risk from Dobbs and new abortion restrictions

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

J&J to emphasize cancer drugs, stop much of its vaccine research

entertainment

leisure time

leisure time

Activists slam private health insurers over coverage restrictions

CDC director unscathed in first congressional testimony

What does generative AI mean for health care? We asked experts

The science behind Janet Jackson's pregnancy at 49

Cancer drug shortages should be causing more outrage

What to do when lifesaving products contribute to climate change

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Death of patient in Alzheimer’s trial raises question of possible risks

Supreme Court strikes down use of affirmative action

Ask STAT: What do you want to know about ChatGPT in medicine?

hotspot

Do masks work? RCTs can't tell us

ReNAgade cuts staff seven months after raising $300 million

Pediatric cancer treatments threatened by a new FDA policy

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Takeda, Janssen join wearable maker to measure scratching

Do masks work? RCTs can't tell us

explore

explore

leisure time

knowledge